Sign inCreate account

Report workspace tools

NCT03119558COMPLETEDanonymous

18F-Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid

Sponsor

Source record

Stanford University

Phase

Source record

EARLY_PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

18F-Florbetaben (Neuraceq®) PET/MRI

Indication / condition

AI-normalized

Cardiac Amyloidosis

Intervention

Source record

18F-Florbetaben (Neuraceq®) PET/MRI

Source & freshness

Source record

NCT ID

NCT03119558

Original source

ClinicalTrials.gov

Source last updated

Jul 17, 2019

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03119558

Title

18F-Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid

Sponsor

Stanford University

Status

COMPLETED

Phase

EARLY_PHASE1

Condition raw

Cardiac Amyloidosis

Condition normalized

Cardiac Amyloidosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

18F-Florbetaben (Neuraceq®) PET/MRI

Target normalized

18F-Florbetaben (Neuraceq®) PET/MRI

Interventions

18F-Florbetaben (Neuraceq®) PET/MRI

Public preview

Source record

Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

18F-Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03119558

Status

COMPLETED

Phase

EARLY_PHASE1

Sponsor

Stanford University

Executive brief

Investment-Ready Snapshot

Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 17, 2019
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03119558

Indication

Cardiac Amyloidosis

Modality

small molecule

Target

18F-Florbetaben (Neuraceq®) PET/MRI

Intervention

18F-Florbetaben (Neuraceq®) PET/MRI

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.